Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid
To access this article, please choose from the options below
Supported by a Translational Research Fellowship (to G.M.) from the European Society of Medical Oncology (ESMO).
PII: S1931-5244(10)00009-5
doi:10.1016/j.trsl.2010.01.002
© 2010 Mosby, Inc. All rights reserved.
